These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 34469032)
1. Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first-line therapy. Fatehi F; Okhovat AA; Panahi A; Ziaaddini B; Rajabally YA; Nafissi S J Peripher Nerv Syst; 2021 Dec; 26(4):469-474. PubMed ID: 34469032 [TBL] [Abstract][Full Text] [Related]
2. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muley SA; Jacobsen B; Parry G; Usman U; Ortega E; Walk D; Allen J; Pasnoor M; Varon M; Dimachkie MM Muscle Nerve; 2020 May; 61(5):575-579. PubMed ID: 31922613 [TBL] [Abstract][Full Text] [Related]
3. Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-Up. Härtig F; Ross M; Dammeier NM; Fedtke N; Heiling B; Axer H; Décard BF; Auffenberg E; Koch M; Rattay TW; Krumbholz M; Bornemann A; Lerche H; Winter N; Grimm A Neurotherapeutics; 2018 Apr; 15(2):439-451. PubMed ID: 29435815 [TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to a Nodal Isoform of Neurofascin in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy. Chauvet E; Blanchard Rohner G; Manel V; Delmont E; Boucraut J; Garcia-Tarodo S Child Neurol Open; 2023; 10():2329048X221149618. PubMed ID: 36816544 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Hu J; Sun C; Lu J; Zhao C; Lin J J Neurol; 2022 Mar; 269(3):1250-1263. PubMed ID: 34120208 [TBL] [Abstract][Full Text] [Related]
6. Characterization of the patients with antibodies against nodal-paranodal junction proteins in chronic inflammatory demyelinating polyneuropathy. Dong M; Tai H; Yang S; Gao X; Pan H; Zhang Z Clin Neurol Neurosurg; 2022 Dec; 223():107521. PubMed ID: 36401951 [TBL] [Abstract][Full Text] [Related]
7. Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. Roux T; Debs R; Maisonobe T; Lenglet T; Delorme C; Louapre C; Leblond V; Viala K J Peripher Nerv Syst; 2018 Dec; 23(4):235-240. PubMed ID: 30203907 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. Shimizu S; Iijima M; Fukami Y; Tamura N; Nakatochi M; Ando M; Nishi R; Koike H; Kaida K; Koga M; Kanda T; Ogata H; Kira JI; Mori M; Kuwabara S; Katsuno M JMIR Res Protoc; 2020 Apr; 9(4):e17117. PubMed ID: 32234705 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study. Liu B; Hu J; Sun C; Qiao K; Xi J; Zheng Y; Sun J; Luo S; Zhao Y; Lu J; Lin J; Zhao C J Neurol; 2023 Sep; 270(9):4288-4295. PubMed ID: 37195346 [TBL] [Abstract][Full Text] [Related]
10. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin. Cirillo G; Todisco V; Tedeschi G Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579 [TBL] [Abstract][Full Text] [Related]
17. Childhood chronic inflammatory demyelinating polyneuropathy: an overview of 10 cases in the modern era. Ware TL; Kornberg AJ; Rodriguez-Casero MV; Ryan MM J Child Neurol; 2014 Jan; 29(1):43-8. PubMed ID: 23364655 [TBL] [Abstract][Full Text] [Related]
18. Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment. Pegat A; Boisseau W; Maisonobe T; Debs R; Lenglet T; Psimaras D; Azoulay-Cayla A; Fournier E; Viala K J Peripher Nerv Syst; 2020 Jun; 25(2):162-170. PubMed ID: 32364302 [TBL] [Abstract][Full Text] [Related]